CELLF BIO Achieves Milestone With First In Human Implantation of BioSphincter
| PFPMX Fund | USD 41.93 0.43 1.02% |
Slightly above 62% of Parnassus Mid's investor base is looking to short. The analysis of overall sentiment of trading Parnassus Mid Cap mutual fund suggests that many investors are alarmed at this time. Parnassus Mid's investing sentiment can be driven by a variety of factors including economic data, Parnassus Mid's earnings reports, geopolitical events, and overall market trends.
Parnassus |
RICHMOND, Va., June 06, 2023 CELLF BIO achieved a major milestone with the worlds first human implantation of BioSphincter, an autologous bioengineered sphincter made of smooth muscle and differentiated neural stem cells. The Phase 1 clinical trial is being conducted to treat patients with fecal incontinence , a condition that affects millions of people worldwide. The implantation surgery was performed by Dr. Jaime Bohl, chief of colon and rectal surgery at the Virginia
Read at finance.yahoo.com
 |
Parnassus Mid Fundamental Analysis
We analyze Parnassus Mid's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Parnassus Mid using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Parnassus Mid based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Ten Year Return
Ten Year Return Comparative Analysis
Parnassus Mid is currently under evaluation in ten year return among similar funds. Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
Parnassus Mid Cap Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Parnassus Mid mutual fund to make a market-neutral strategy. Peer analysis of Parnassus Mid could also be used in its relative valuation, which is a method of valuing Parnassus Mid by comparing valuation metrics with similar companies.
Peers
Parnassus Mid Related Equities
| SCRYY | SCOR PK | 3.60 | ||||
| SVII | Spring Valley | 0.09 | ||||
| FPCG | First Physicians | 0.00 | ||||
| 70082LAB3 | 70082LAB3 | 0.00 | ||||
| XTWO | Bondbloxx ETF | 0.06 | ||||
| VIASP | Via Renewables | 0.36 | ||||
| MSTSX | Morningstar Unconstrained | 0.67 | ||||
| XTWY | Bondbloxx ETF | 0.69 | ||||
| VMCPX | Vanguard Mid | 1.07 |
Other Information on Investing in Parnassus Mutual Fund
Parnassus Mid financial ratios help investors to determine whether Parnassus Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Parnassus with respect to the benefits of owning Parnassus Mid security.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |